Table 1.

Patients’ baseline characteristics

CharacteristicTN (n = 61)R (n = 59)
Age, y66 (42-79)63 (41-84)
Sex
 Male42 (69)43 (73)
 Female19 (31)16 (27)
Rai stage
 0-II35 (57)29 (49)
 III-IV26 (43)30 (51)
White blood cell count, ×109/L76 (9-232)28 (2-189)
Absolute lymphocyte count, ×109/L68 (2-197)26 (0-177)
Absolute neutrophil count, ×109/L4 (0-18)3 (0-9)
Hemoglobin level, g/dL12.3 (8.9-15.9)12.5 (8.6-16.4)
Platelet count, ×109/L141 (45-325)115 (32-267)
B2M level, mg/L3.8 (1.4-10.5)4 (1.5-18.3)
eGFR, mL/min73 (42-127)70 (36-118)
IgHV gene status
 Mutated18 (37)8 (17)
 Unmutated31 (63)39 (83)
 No product/missing1212
FISH
 Del13q20 (33)15 (31)
 Normal8 (13)8 (16)
 +1213 (22)7 (14)
 Del11q15 (25)13 (27)
 Del17p4 (7)6 (12)
 Missing110
Karyotype
 Noncomplex42 (82)22 (63)
 Complex9 (18)13 (37)
 Missing1024
No. of previous treatmentsn/a2 (1-9)
Fludarabine refractoryn/a10 (17)
  • Data are presented as median (range) or no. (%).

  • eGFR, estimated glomerular filtration rate; IgHV, immunoglobulin heavy chain variable region; n/a, not applicable.